Author: Srivastava, Sukrit; Kamthania, Mohit; Singh, Soni; Saxena, Ajay K; Sharma, Nishi
Title: Structural basis of development of multi-epitope vaccine against Middle East respiratory syndrome using in silico approach Document date: 2018_11_21
ID: 33h22ikl_69
Snippet: In this study, we propose the design of two MEVs against MERS-CoV that consisted of CTL and HTL epitopes. The selected CTL and HTL epitopes were validated by in silico methods for their molecular interaction with HLA alleles and TAP (for CTL epitopes). The population coverage by the designed MEVs is as high as 94% of the world population. Both MEVs were found to contain IFN-γ epitopes and B-cell discontinuous epitopes. Moreover, they also showed.....
Document: In this study, we propose the design of two MEVs against MERS-CoV that consisted of CTL and HTL epitopes. The selected CTL and HTL epitopes were validated by in silico methods for their molecular interaction with HLA alleles and TAP (for CTL epitopes). The population coverage by the designed MEVs is as high as 94% of the world population. Both MEVs were found to contain IFN-γ epitopes and B-cell discontinuous epitopes. Moreover, they also showed stable interaction with the immunoreceptor TLR-3. On the basis of the design and in silico validation of both the CTL and HTL MEVs, their joint administration is predicted to induce humoral and cell-mediated immune response. Codon-based cDNAs of both MEVs are predicted to have high expression in the mammalian host cell line (human); hence, they could be cloned and expressed at the laboratory level for in vivo trials on humanized HLA-expressing mice for further study.
Search related documents:
Co phrase search for related documents- cell line and high expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- cell line and hla allele: 1, 2
- cell line and host cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- cell line and HTL CTL epitope: 1, 2
- cell line and HTL mev: 1, 2, 3
- cell line and human host cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- cell line and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- cell line and laboratory level: 1, 2, 3
- cell line and mammalian human host cell line: 1, 2, 3, 4, 5
- cell line and molecular interaction: 1, 2, 3, 4, 5, 6
- cell line and population coverage: 1, 2, 3, 4
- cell line and silico method: 1
- cell line and stable interaction: 1, 2, 3, 4
- cell line and TAP hla allele: 1
- cell line and world population: 1, 2, 3, 4
- cell mediate and high expression: 1, 2
- cell mediate and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- cell mediate and molecular interaction: 1
Co phrase search for related documents, hyperlinks ordered by date